Otarmeni (lunsotogene parvec-cwha), a Gene Therapy for Sensorineural Hearing Loss

Summary: A new FDA-approved gene therapy called Otarmeni is changing the lives of people born with a specific type of severe hearing loss. This hearing loss is caused by a missing OTOF gene. Instead of using a cochlear implant, doctors inject a liquid into the ear. This liquid contains helpful viruses that deliver the missing DNA directly to the cells. This allows the ear to start working and sending sound signals to the brain naturally. In studies, 80% of kids had better hearing, and many kept improving, with some reaching normal hearing after a year.

For more details, see rssapp-empr-com at empr.com/news/otarmeni-lunsotogene-parvec-cwha-a-gene-therapy-for-sensorineural-hearing-loss/ (opens in new tab)